Allscripts (NASDAQ: MDRX) reported Q2 EPS of $0.09, in-line with the analyst estimate of $0.09. Revenue for the quarter came in at $354 million versus the consensus estimate of $353.12 million.

"We had a strong quarter that reflects the impact of a consistent focus on client execution," said Paul M. Black, President and Chief Executive Officer of Allscripts. "We have strengthened our core clinical and revenue cycle solutions, partnered with our clients to achieve their Meaningful Use 2 objectives, solidified our leadership in growth markets like population health management and have moved aggressively to become more operationally efficient."

"The benefit of this corporate focus is demonstrated by new, expanded and renewed commitments to Allscripts. We signed two new Allscripts Sunrise agreements in the second quarter, including a major new international client, totaling 25 new Allscripts Sunrise client site commitments since January 2013."

"The quarter also marks an important milestone as bookings, revenue and Adjusted EBITDA all grew year-over-year for the first time in two years. Operating expenses declined as operational efficiency initiatives that commenced last year began to pay off. Looking ahead, our pipeline of new business is strengthening globally. We continue to see ample opportunities to grow with our clients, increase our footprint and help providers transform healthcare by delivering on the promise of consumer engagement and wellness and prevention services."

For earnings history and earnings-related data on Allscripts (MDRX) click here.